OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Fenske on the Future of Daratumumab in MCL

May 7th 2019

Timothy Fenske, MD, MS, associate professor, Medical College of Wisconsin, discusses the future of daratumumab (Darzalex) in mantle cell lymphoma (MCL).

Dr. Leitao Discusses the Role of HIPEC in Advanced Ovarian Cancer

May 7th 2019

Mario M. Leitao Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the role of HIPEC in patients with advanced ovarian cancer.

Dr. Kelly Discusses the Treatment of Patients With ALK+ NSCLC

May 7th 2019

Ronan J. Kelly, MD, MBA, chief of oncology for the ten Baylor Scott and White Health's North Texas Cancer Centers and director of oncology on the campus of Baylor Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the treatment of patients with ALK-positive non–small cell lung cancer.

Dr. Higano on the Toxicity of Androgen Receptor Inhibitors in CRPC

May 7th 2019

Celestia Higano, MD, FACP, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, professor, Department of Medicine and Urology, University of Washington, Seattle Cancer Care Alliance, discusses the toxicity of androgen receptor inhibitors in castration-resistant prostate cancer.

Dr. McGregor on Implications of the FDA Approval of Pembrolizumab/Axitinib in RCC

May 4th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the clinical implications of the FDA approval of pembrolizumab (Keytruda) and axitinib (Inlyta) in advanced renal cell carcinoma (RCC).

Dr. Grivas on Investigational Immunotherapy Approaches in Localized Bladder Cancer

May 4th 2019

Petros Grivas, MD, PhD, clinical director of the Genitourinary Cancers Program and associate professor, Department of Medicine, Division of Oncology, University of Washington, and medical oncologist, Seattle Cancer Care Alliance, discusses investigational immunotherapy approaches in localized bladder cancer.

Dr. Einstein on Biochemical Recurrence in Prostate Cancer

May 4th 2019

David J. Einstein, MD, instructor of medicine at Harvard Medical School, and attending physician of medicine at Beth Israel Deaconess Medical Center, discusses biochemical recurrence in patients with prostate cancer.

Dr. Stahel on Treatment Sequencing in Stage IV NSCLC

May 3rd 2019

Rolf A. Stahel, MD, professor in the oncology clinic, University Hospital, Zurich, discusses treatment sequencing in stage IV non–small cell lung cancer.

Dr. Addeo Discusses the Need for Biomarkers in NSCLC

May 3rd 2019

Alfredo Addeo, MD, consultant medical oncologist, University Hospital of Geneva, discusses the need for effective biomarkers in non–small cell lung cancer.

Unanswered Questions With the Role of TMB in NSCLC

May 3rd 2019

Umberto Malapelle, PhD, assistant professor, University of Naples Federico II, discusses unanswered questions regarding the role of tumor mutational burden in non–small cell lung cancer.

Dr. Mortimer on Adjuvant Therapy in Early-Stage HER2+ Breast Cancer

May 3rd 2019

Joanne Mortimer, MD, associate director for Education and Training, Comprehensive Cancer Center, Baum Family Professor in Women’s Cancers, vice chair and professor, Department of Medical Oncology & Therapeutics Research, director, Women’s Cancer Programs, City of Hope, discusses adjuvant therapy in early-stage HER2-positive breast cancer.

Dr. Dhakal on Early Data With BiTEs in Multiple Myeloma

May 3rd 2019

Binod Dhakal, MD, assistant professor, Medical College of Wisconsin, discusses early data with bispecific T-cell engager (BiTE) antibody constructs in multiple myeloma.

Dr. Sonpavde on Accelerated Approval of Erdafitinib in Bladder Cancer

May 3rd 2019

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the FDA accelerated approval of erdafitinib (Balversa) in bladder cancer.

Dr. Winer Discusses the FDA Approval of Ivosidenib in AML

May 2nd 2019

Eric Stephen Winer, MD, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the FDA approval of ivosidenib in acute myeloid leukemia (AML).

Dr. Sabbatini on Promising Therapies in Newly Diagnosed Ovarian Cancer

May 2nd 2019

Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses promising therapies in newly diagnosed ovarian cancer.

Dr. Glaser on Managing Radiation-Induced AEs in Early Breast Cancer

May 2nd 2019

Scott Glaser, MD, assistant clinical professor of radiation oncology, City of Hope, discusses strategies for managing radiation-induced adverse events in patients with early-stage breast cancer.

Dr. Nadler Discusses the IMpower131 Study in Squamous NSCLC

May 2nd 2019

Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the IMpower131 study in squamous metastatic non–small cell lung cancer.

Dr. Abedin Discusses Key Updates in CLL

May 2nd 2019

Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses key updates in the treatment of patients with chronic lymphocytic leukemia.

Dr. Shah Discusses Ongoing Research With CAR T-Cell Therapy

May 2nd 2019

Nirav N. Shah, MD, assistant professor, Medical College of Wisconsin, discusses ongoing research with CAR T-cell therapy.

Dr. Anthony on Sequencing Strategies for Patients With NETs

May 2nd 2019

Lowell B. Anthony, MD, FACP, chief, Division of Medical Oncology, University of Kentucky Markey Cancer Center, discusses sequencing strategies for patients with gastroenteropancreatic neuroendocrine tumors.